PREPRINT (not peer reviewed)

Aquahenosis: A non-pharmacological altered state of consciousness induced by Floatation-REST

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: PsyArXiv
Date: 2026-01-15
Source: PsyArXiv
DOI: Unavailable
PubMed: Unavailable

Authors

Theo Tobel Aidan Cone Emily M Choquette McKenna Garland Micah Johnson Keller Mink Caitlin Lynch Joel Frohlich Justin Feinstein Nicco Reggente

Watch author

Derived topics and classifications

psilocybin Depression Anxiety Mechanism of Action Consciousness Spirituality Randomized Controlled Trial Randomized Controlled Trial

Citation graph

0 referenced DOIs found in stored source metadata. 0 indexed papers cite this DOI.

Open citation network

Related papers

Role of the Serotonin 2A Receptor in Psilocybin-induced Altered States of Consciousness (PDR-Study)ClinicalTrials.gov · 2025-05-28 Effect of MDMA-assisted therapy on mood and anxiety symptoms in advanced-stage cancer (EMMAC): study protocol for a double-blind, randomised controlled trial.Trials · 2024-05-21 S1 Appendix - Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trialFigshare · 2025-09-19 Engaging Mood Brain Circuits with Psilocybin (EMBRACE): a study protocol for a randomized, placebo-controlled and delayed-start, neuroimaging trial in depression.Trials · 2024-07-03 Role of the Serotonin 5-HT2A Receptor in Mescaline-induced Altered States of ConsciousnessClinicalTrials.gov · 2023-03-29 Effects of Serotonin Transporter Inhibition on the Subjective Response to Psilocybin in Healthy SubjectsClinicalTrials.gov · 2020-12-01 A Phase III, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With Treatment-resistant DepressionClinicalTrials.gov · 2026-08-10 A Phase III, Multicentre, Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Treatment-resistant DepressionClinicalTrials.gov · 2026-08-10